CureVac N.V (NASDAQ:CVAC)’s traded shares stood at 0.59 million during the last session, with the company’s beta value hitting 2.49. At the close of trading, the stock’s price was $4.10, to imply a decrease of -1.91% or -$0.08 in intraday trading. The CVAC share’s 52-week high remains $5.28, putting it -28.78% down since that peak but still an impressive 46.1% since price per share fell to its 52-week low of $2.21. The company has a valuation of $919.66M, with an average of 1.78 million shares in intraday trading volume over the past 10 days and average of 745.23K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for CureVac N.V (CVAC), translating to a mean rating of 2.17. Of 2 analyst(s) looking at the stock, 0 analyst(s) give CVAC a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy.
CureVac N.V (NASDAQ:CVAC) trade information
After registering a -1.91% downside in the last session, CureVac N.V (CVAC) has traded red over the past five days. The 5-day price performance for the stock is -2.61%, and 32.26% over 30 days. With these gigs, the year-to-date price performance is 20.23%. Short interest in CureVac N.V (NASDAQ:CVAC) saw shorts transact 3.82 million shares and set a 6.54 days time to cover.
The extremes give us $21 and $37 for target low and target high price respectively. As such, CVAC has been trading -802.44% off suggested target high and -412.2% from its likely low.
CureVac N.V (CVAC) estimates and forecasts
Looking at statistics comparing CureVac N.V share performance against respective industry, we note that the company has outperformed competitors. CureVac N.V (CVAC) shares are 10.22% up over the last 6 months, with its year-to-date growth rate higher than industry average at 156.25% against 16.60%.
CVAC Dividends
CureVac N.V has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is POINT72 ASSET MANAGEMENT, L.P. with 2.42 million shares, or about 1.0802% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $8.24 million.
We also have iShares Biotechnology ETF and iShares Core MSCI EAFE ETF as the top two Mutual Funds with the largest holdings of the CureVac N.V (CVAC) shares. Going by data provided on Oct 31, 2024 , iShares Biotechnology ETF holds roughly 651.42 shares. This is just over 0.29% of the total shares, with a market valuation of $2.67 million. Data from the same date shows that the other fund manager holds a little less at 582.29, or 0.26% of the shares, all valued at about 2.39 million.
